Barbara
Cortese
ab,
Stefania
D'Amone
a,
Giuseppe
Gigli
acd and
Ilaria Elena
Palamà
*a
aInstitute Nanoscience CNR (NNL, CNR-NANO), via Arnesano, Lecce, Italy. E-mail: ilariaelena.palama@nano.cnr.it
bDepartment of Physics, University Sapienza, P. le A. Moro 5, Rome, Italy
cDept. Matematica e Fisica ‘Ennio De Giorgi’, University of Salento, via Monteroni, Lecce, Italy
dItalian Institute of Technology (IIT) – Center for Biomolecular Nanotechnologies, via Barsanti, Arnesano, Italy
First published on 24th June 2016
Correction for ‘Sustained anti-BCR–ABL activity with pH responsive imatinib mesylate loaded PCL nanoparticles in CML cells’ by Barbara Cortese et al., Med. Chem. Commun, 2015, 6, 212–221.
This MedChemComm paper presents a comprehensive study of the synthesis of the reported PCL nanoparticles, pH release of the loaded drug, the colocalization of the nanoparticles in cells, and in vitro evidence that the drug release was active against a specific molecular target, the oncoprotein BCR–ABL.
The Biomaterials Science paper reports the combination of these PCL nanoparticles with polyelectrolyte nanocomplexes for the dual delivery of two drugs, imatinib mesylate and doxorubicin.
*I. E. Palamà, B. Cortese, S. D'Amone, V. Arcadio and G. Gigli, Biomater. Sci., 2015, 3, 361–372.
This journal is © The Royal Society of Chemistry 2016 |